Caroline Blevins
Family Medicine · North Chesterfield, VANPI 1295115020
Payments from drug & device makers
Across 338 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$970
- AbbVie$754
- Pfizer$660
- AstraZeneca$523
- Lilly USA, LLC$455
- Amgen$214
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,59399%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 64 | $970 |
| AbbVie(2 entities) | 50 | $754 |
| Pfizer | 45 | $660 |
| AstraZeneca | 22 | $523 |
| Lilly USA, LLC | 30 | $455 |
| Amgen(2 entities) | 15 | $214 |
| Boehringer Ingelheim | 12 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $182 |
| Otsuka America Pharmaceutical, Inc. | 7 | $169 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $159 |
| Bayer | 8 | $137 |
| Abbott | 8 | $132 |
| Boston Scientific | 1 | $130 |
| GSK | 7 | $111 |
| Inspire Medical Systems, Inc. | 4 | $109 |
| Novartis | 7 | $96 |
| Dexcom, Inc. | 4 | $74 |
| Dynavax Technologies Corporation | 3 | $59 |
| Merck | 3 | $58 |
| Phadia US Inc. | 2 | $46 |
| Astellas Pharma US Inc | 3 | $45 |
| Exact Sciences | 3 | $44 |
| Medtronic(2 entities) | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Edwards Lifesciences | 1 | $17 |
| Exeltis, USA Inc. | 1 | $15 |
| Pulmonx Corporation | 1 | $15 |
| Ardelyx, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$179
- AIRSUPRA$179
- LOKELMA$179
- BREZTRI$179
- WATCHMAN Access System$130
How this compares
$5,656 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 154 | $202,574 |
| OzempicSemaglutide | 123 | $197,648 |
| EliquisApixaban | 153 | $132,447 |
| FarxigaDapagliflozin Propanediol | 108 | $125,227 |
| MounjaroTirzepatide | 54 | $55,727 |
| JanuviaSitagliptin Phosphate | 30 | $45,553 |
| TrulicityDulaglutide | 25 | $39,478 |
| XareltoRivaroxaban | 30 | $32,786 |
| EntrestoSacubitril/Valsartan | 20 | $27,140 |
| RybelsusSemaglutide | 18 | $22,941 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $18,631 |
| Repatha SureclickEvolocumab | 11 | $18,587 |
| LinzessLinaclotide | 15 | $16,861 |
| Spiriva HandihalerTiotropium Bromide | 18 | $11,166 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $10,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $970 | $220,590141 claims |
| Boehringer IngelheimJardiance | $197 | $202,574154 claims |
| PfizerEliquis, Prempro | $660 | $137,066165 claims |
| AstraZenecaFarxiga, Symbicort | $523 | $131,687129 claims |
| Lilly USA, LLCMounjaro, Trulicity | $455 | $95,20579 claims |
| MerckJanuvia | $58 | $45,55330 claims |
| Johnson & JohnsonXarelto | $13 | $32,78630 claims |
| NovartisEntresto | $96 | $27,14020 claims |
| GSKBreo Ellipta, Incruse Ellipta | $111 | $22,83650 claims |
| AbbVieLinzess, Synthroid | $754 | $19,21866 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $12 | $4,57212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in North Chesterfield
- Jerome DanielNorth Chesterfield$779K
- Kara Foster WeissNorth Chesterfield$136K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.